Mounjaro shelf life after opening: what the official guidance actually says

What the SmPC actually specifies about tirzepatide shelf life after opening

The Mounjaro SmPC, the authoritative product document reviewed by the MHRA, is specific: an opened KwikPen may be kept for a maximum of 30 days. During that time it can be stored either in a refrigerator (2–8°C) or at room temperature up to 30°C. What the document does not permit is leaving the pen somewhere warmer than that, a bathroom cabinet in summer, a car glovebox, or a window ledge can all exceed 30°C without feeling obviously hot.

The pen must never be frozen. If a pen has been accidentally frozen, the medicine should not be used even if it looks unchanged. The SmPC also specifies that Mounjaro should be protected from light, so the cap should stay on between injections. For the full technical detail, the Mounjaro SmPC on the eMC is the definitive source and is publicly accessible.

One practical point worth knowing: the tirzepatide shelf life after opening is tied to the date of first use, not to when you removed the pen from the fridge. If you take a pen out of cold storage but do not use it for two days, those two days still count toward the 30-day window once you puncture it. Keep a note of the first-use date somewhere simple, the back of the box works well.

Why an opened pen behaves differently from an unopened one

Before first use, an unopened Mounjaro pen can be stored in a refrigerator until the expiry date printed on the label, or at room temperature for up to 21 days before opening. Once the pen is punctured, that longer pre-opening period no longer applies. You can read more about those pre-opening rules on our page covering Mounjaro shelf life when unopened.

The shift in stability after opening reflects the nature of the formulation rather than any defect in the pen. Biological medicines like tirzepatide are sensitive to repeated temperature fluctuation, light exposure and, once the septum is punctured, any chance of contamination. The 30-day post-opening limit builds in a margin that accounts for real-world handling, the kind that happens when you store the pen in the fridge door next to the milk and occasionally leave it on the kitchen counter while you prepare your injection site.

This is also why the pen is designed as a multi-dose device rather than a series of single-use injections: four weekly doses from one pen is clinically convenient, but it does mean the pen is in use for up to 28 days, which sits comfortably within the 30-day limit only if storage conditions are maintained throughout. Missing a week or delaying a dose can push you close to or beyond that boundary.

What to do if you are approaching or have passed the 30-day mark

If you realise you are on day 28 or 29 of an open pen with one dose remaining, you can use that dose provided the pen has been stored correctly and the medicine looks as expected: a clear, colourless to slightly yellow solution with no particles. The NHS medicines page for tirzepatide advises checking the liquid before each injection and not using it if it appears discoloured or cloudy.

If the 30 days have passed, the guidance is unambiguous: discard the pen. It is not a question of whether the medicine looks or feels different. The stability data that supports the 30-day limit does not extend beyond it, so there is no basis for confidence that the medicine remains at full potency. Disposing of the pen correctly means using a sharps container; our FAQs cover disposal queries if you are unsure where to start.

A missed dose is a separate question from an expired pen. If you miss an injection because you realised the pen had lapsed, contact your prescriber rather than doubling up or adjusting your own schedule. Timing and titration decisions sit with your clinical team. For questions about how a treatment gap might affect your progress, the team at nume's patient support are available seven days a week.

The broader picture: why these rules matter for your results

People sometimes ask whether strict storage rules are just manufacturer caution. They are not. Temperature excursions and degradation are documented concerns with biological medicines, and sub-potent injections are one reason some patients on tirzepatide see less progress than the clinical evidence suggests they should. The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average weight reductions of around 20–21% at the 15mg dose over 72 weeks, but that evidence was generated under controlled conditions where medicine integrity was guaranteed throughout.

Keeping your pen within its storage limits is one of the simplest things you can do to ensure you get what the trials showed is achievable, and our page on Mounjaro shelf life brings together the key rules in one place if you want a quick reference. It also connects to the wider question of sourcing: counterfeit or improperly stored pens sold without a prescription and clinical assessment carry no such guarantee. The MHRA has made clear that fake pens are a genuine safety risk, not a theoretical one. Buying through a GPhC-registered pharmacy you can verify on the public register is the baseline for knowing your medicine has been handled properly before it reaches you.

If you are thinking about starting treatment or want to understand more about what the programme involves, our weight-loss treatments page explains what a clinical consultation with nume covers, including the checks our prescribers carry out before any medicine is dispensed. Understanding whether Mounjaro has a shelf life and how those rules apply across a full treatment course is worth reading alongside this page, as is our guide to life after Mounjaro for patients thinking ahead to what comes next.